



VICORE PHARMA AB

Webcast – MHRA approval for COVID-19 trial with VP01, April 2020




COVID-19






VP01 IN COVID-19

Renin Angiotensin System (RAS) in COVID-19 - Background






VP01 IN COVID-19 - RAS






VP01 IN COVID-19 - RAS






VP01 IN COVID-19 - RAS





THE CoV-2 VIRUS CREATES AN IMBALANCE IN RAS






VP01 IN COVID-19 - MODE OF ACTION

VP01 is a first in class small molecule stimulating the angiotensin type 2 receptor (AT2R)

Angiotensin II has 2 receptors with opposite actions

In COVID 19, ACE2 is hi-jacked resulting in AT1R/AT2R inbalance


AT2R directly, VP01 will counteract the ANG II effects






VP01 IN COVID-19 – ATTRACT

ATTRACT – Angiotensin II Type Two Receptor Agonist in COVID-19 Trial






VP01 IN COVID-19 STUDY DESIGN



A randomized, double-blind, placebo-controlled phase II trial investigating the efficacy of VP01 on disease progression and outcome in hospitalized patients with COVID-19




- Patients will be monitored for disease progression, as well as clinical outcome
 - The study will also measure infection parameters and biomarkers
- Approved by MHRA on April 27
 - We will initially have one site and anticipate to start in approximately 2 weeks with completion of the clinical part in 3 months



VP01 IN COVID19

Summary





VP01 IN COVID-19 – SUMMARY

The COVID-19 is an emerging pandemic for which there currently is no cure

The virus utilizes the enzyme ACE2 to infect the alveolar cells

ACE2 normally breaks down pro-inflammatory ANGII to molecules that are protective via AT2R

Binding of virus incapacitates ACE2 leading to an imbalance in the RAS system, promoting inflammation and development of ARDS

VP01, an AT2R agonist, is independent of ACE2 and could therefore help to prevent the lung damaging inflammation in COVID-19

Vicore have received approval by the MHRA in record time to start the phase II trial ATTRACT, in COVID-19

The study will start within 2 weeks and we expect 3 months for completion

